FindTrial
Sign In

Efficacy and safety of intraoperative Cell Saver in cardiac surgery associated with cardiopulmonary bypass circuit

Efficacy and safety of intraoperative Cell Saver in cardiac surgery associated with cardiopulmonary bypass circuit: a prospective, randomized and controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003209
Enrollment
Unknown
Registered
2013-05-05
Start date
2013-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiopathy

Interventions

1:cell saver and autotransfusion
2:without cell saver and autotransfusion

Sponsors

Zhejiang Province People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. scheduled for cardiac surgery; 2. firsttime procedures requiring cardiopulmonary bypass; 3. aged >=18 years; 4. American Society of Anesthesiologist (ASA) classification of I-III; 5. provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. existing inflammatory diseases; 2. congenital or acquired platelet/clotting disorders; 3. use of anti-platelet agents in the week prior to surgery; 4. lung dysfunction (forced vital capacity (FVC) or forced expiratory volume in 1 s (FEV1) 200 umol/L).

Design outcomes

Primary

MeasureTime frame
Any allogeneic blood transfusion from the beginning of operation to 24h after operation;—

Secondary

MeasureTime frame
The number of units of RBCs, FFP, or platelets transfused from the beginning of operation to 24 h after operation;Hematology and biochemistry variables;—

Countries

China

Contacts

Public Contactshe-liang SHEN
hz-ssl@163.com+86 13857194168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026